Start here if you're new
what it is
Interpace sells genetic tests that help doctors decide whether a thyroid or pancreatic nodule looks dangerous.
how it gets paid
Last year Interpace Bioscience made $47M in revenue.
why it's growing
Revenue grew 36.0% last year. EPS was $0.07, up 133% vs. prior year.
what just happened
Revenue hit $30M, up 237% vs. prior year.
At a glance
C balance sheet — red flag territory — real financial stress
25/100 earnings predictability — expect surprises
14.2x trailing p/e — the market's not buying it — or you found a deal
$0.42 fy2024 eps est
$2B fy2026 rev est
xvary composite: 25/100 — weak
What they do
Interpace sells genetic tests that help doctors decide whether a thyroid or pancreatic nodule looks dangerous.
Doctors do not buy vibes. They buy test results that change treatment. Interpace turned that into a 61.3% gross margin (gross margin → money left after paying to run each test → so what: the test menu has pricing power). With 111 employees and just $1 million of long-term debt, you are looking at a small lab that does not need a giant empire to matter.
How they make money
$47M
annual revenue · their business grew +36.0% last year
total revenue
$47M
+36.0%
The products that matter
molecular cancer diagnostics
Thyroid Cancer Testing
$40M guided · 100% of target revenue
this is the current company. management's $40M 2026 revenue target is entirely tied to thyroid testing, so your upside and your concentration risk are the same thing.
all-in revenue driver
discontinued pancreatic assay
PancraGEN® Test
$7M legacy revenue
this product generated about $7M before the company stopped offering it in 2023 after CMS reimbursement changes. that's a useful reminder that payor decisions can end a product story quickly.
reimbursement lesson
remaining non-core business
Legacy / Other
sub-scale and fading
the page data shows legacy and other activity at $7M and discontinued. that means the company has less diversification than the old product list suggests.
not the growth case
Key numbers
18.9%
operating margin
Operating margin → profit after running the business → so what: Interpace keeps about 19 cents from each sales dollar before interest and taxes, which is rare for an $8 million microcap.
61.3%
gross margin
Gross margin → money left after paying to deliver each test → so what: the lab work is not being sold like a commodity.
$1M
long-term debt
Long-term debt → borrowings due over years → so what: debt is only 10% of capital, which is light for a company this small.
36.0%
annual revenue growth
Revenue growth → how much more money came in than last year → so what: sales rose far faster than most mature lab businesses.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $1M (10% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for IDXG right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $30M, up 237% vs. prior year.
EPS was $0.07, up 133% vs. prior year. Gross margin was 61.3%, which means the real story was not just more tests, but profitable tests.
$12M
revenue
$0.07
eps
61.3%
gross margin
the number that mattered
$30M matters because one quarter produced about 64% of the company's $47M annual revenue base, which tells you the business mix changed fast.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is single-test dependence in thyroid diagnostics. when 100% of a $40M revenue target rides on one category, you do not have diversification. you have concentration.
med
thyroid concentration
The current growth case points 100% of the guided $40M 2026 revenue to thyroid testing. If ordering volume weakens or a competing assay wins share, the entire model feels it.
Impact: this puts effectively all forward revenue concentration in one clinical lane.
med
reimbursement pressure
PancraGEN was stopped after CMS reimbursement changes. That is not ancient history. It is a live example of how payor policy can damage test economics in this business.
Impact: pricing or coverage changes can hit both revenue and confidence at the same time.
med
thin cash and balance sheet flexibility
The company shows $1.42M of cash, a C balance sheet grade, and price stability of just 5/100. Small companies can survive that. They do not get to ignore it.
Impact: any stumble can force financing, delay strategy, or weaken listing ambitions.
A reimbursement setback on the thyroid business would pressure the revenue base that management wants to scale to $40M, while a thin cash position leaves little room to absorb mistakes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
milestone
Nasdaq uplist progress
The planned 2026 uplist is the obvious catalyst. Watch for an actual application, exchange acceptance, and any steps needed to satisfy listing standards.
revenue
whether the $40M target starts showing up in reported numbers
Guidance is a promise. Reported revenue is proof. For a company this small, the gap between those two is the whole debate.
risk
any reimbursement updates around thyroid testing
The company already lost a $7M product line after CMS changes. If the thyroid business sees similar pressure, the stock will feel it quickly.
trading
liquidity and volatility
With an $8M market cap and price stability of 5/100, thin volume can create large moves that tell you more about liquidity than fundamentals.
Analyst rankings
earnings predictability
25 / 100
in human-speak, analysts do not view this as a smooth quarterly model. expect uneven results and sharper reactions.
balance sheet grade
C
This is below average balance-sheet quality. translation: if operations wobble, the capital structure does not give you much padding.
risk rank
5
Safer than only 5% of stocks in the source set. That is the opposite of a defensive name.
source: institutional data
Institutional activity
institutional ownership data for IDXG is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive